Jefferies Group Reiterates $41.00 Price Target for Envision Healthcare (EVHC)

Jefferies Group set a $41.00 price objective on Envision Healthcare (NYSE:EVHC) in a research note issued to investors on Tuesday, December 19th. The brokerage currently has a buy rating on the stock. Jefferies Group also issued estimates for Envision Healthcare’s Q4 2017 earnings at $0.44 EPS, FY2017 earnings at $2.48 EPS, Q1 2018 earnings at $0.47 EPS, Q2 2018 earnings at $0.57 EPS, Q3 2018 earnings at $0.66 EPS, Q4 2018 earnings at $0.70 EPS and FY2018 earnings at $2.40 EPS.

A number of other equities analysts also recently commented on the stock. KeyCorp set a $67.00 price objective on shares of Envision Healthcare and gave the stock a buy rating in a report on Wednesday, November 1st. Cantor Fitzgerald reissued a hold rating and set a $30.00 price target on shares of Envision Healthcare in a report on Tuesday, November 14th. Canaccord Genuity reissued a buy rating and set a $32.00 price target (down previously from $68.00) on shares of Envision Healthcare in a report on Thursday, November 2nd. Credit Suisse Group initiated coverage on shares of Envision Healthcare in a research note on Monday, December 11th. They set an outperform rating and a $36.00 price objective on the stock. Finally, Bank of America cut their price objective on shares of Envision Healthcare from $72.00 to $60.00 and set a buy rating on the stock in a research note on Monday, October 9th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average target price of $40.73.

Envision Healthcare (NYSE:EVHC) traded down $0.13 on Tuesday, hitting $35.72. 1,963,612 shares of the company traded hands, compared to its average volume of 2,631,711. Envision Healthcare has a twelve month low of $23.77 and a twelve month high of $73.00. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.01 and a quick ratio of 3.00. The firm has a market capitalization of $4,340.00, a PE ratio of -23.97, a PEG ratio of 1.00 and a beta of 0.57.

Envision Healthcare (NYSE:EVHC) last posted its quarterly earnings results on Tuesday, October 31st. The company reported $0.73 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.81 by ($0.08). The business had revenue of $1.99 billion during the quarter, compared to analysts’ expectations of $2.03 billion. Envision Healthcare had a negative net margin of 6.39% and a positive return on equity of 4.88%. The company’s quarterly revenue was up 142.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.13 EPS. research analysts expect that Envision Healthcare will post 2.49 earnings per share for the current year.

Envision Healthcare announced that its Board of Directors has initiated a share repurchase program on Monday, September 18th that authorizes the company to buyback $250.00 million in shares. This buyback authorization authorizes the company to reacquire up to 4.5% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

A number of institutional investors have recently made changes to their positions in EVHC. Exane Derivatives acquired a new position in shares of Envision Healthcare during the third quarter worth approximately $475,000. Stonebridge Capital Management Inc. lifted its holdings in shares of Envision Healthcare by 87.0% during the third quarter. Stonebridge Capital Management Inc. now owns 30,329 shares of the company’s stock worth $1,364,000 after buying an additional 14,111 shares during the last quarter. Honeywell International Inc. lifted its holdings in shares of Envision Healthcare by 17.4% during the third quarter. Honeywell International Inc. now owns 542,100 shares of the company’s stock worth $24,367,000 after buying an additional 80,200 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in shares of Envision Healthcare by 5.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 632,195 shares of the company’s stock worth $39,620,000 after buying an additional 33,587 shares during the last quarter. Finally, Nomura Holdings Inc. acquired a new position in shares of Envision Healthcare during the second quarter worth approximately $797,000.

ILLEGAL ACTIVITY WARNING: “Jefferies Group Reiterates $41.00 Price Target for Envision Healthcare (EVHC)” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://ledgergazette.com/2018/01/13/envision-healthcare-evhc-pt-set-at-41-00-by-jefferies-group.html.

Envision Healthcare Company Profile

Envision Healthcare Holdings, Inc, formerly CDRT Holding Corporation, is a holding company. The Company, through its subsidiary, provides physician-led medical services in the United States. It operates in two segments: EmCare Holdings, Inc (EmCare) and American Medical Response, Inc (AMR). Its EmCare segment is a provider of integrated facility-based and post-acute care physician services to healthcare facilities in the United States.

Analyst Recommendations for Envision Healthcare (NYSE:EVHC)

Receive News & Ratings for Envision Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envision Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply